Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BrightStar-2: Brigatinib Plus Chemotherapy or LCT in ALK+ Advanced NSCLC
NCT06522360Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of brigatinib in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Dec 2024; status: withdrawn.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06522360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06522360.